Fully Enrolled CYPRESS Phase 3 Trial to Test Ampreloxetine in Symptomatic Neurogenic Orthostatic Hypotension of MSA
A pivotal phase 3 study explores ampreloxetine's potential to treat neurogenic orthostatic hypotension in multiple system atrophy patients, aiming for FDA approval.